Study identifier:NIS-NDE-SER-2007/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Evaluation of treatment outcomes in schizophrenic patients taking part in the integrated care program - a single-country, multi-centre non-interventional study
schizophrenia
-
No
-
All
20
Observational
18 Years - 65 Years
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
acromion GmbH, Frechen
Purpose of this non-interventional study (NIS) is to assess the effect of the participation in an integrated care program on treatment outcomes in patients treated with Seroquel for schizophrenia.
Location
Location
Hamburg, Germany
Location
Oldenburg, Germany
Location
Berlin, Germany
Location
Spremberg, Germany
Location
Mittweida, Germany
Location
Zittau, Germany
Location
Munster, Germany
Location
Stolberg, Germany
Arms | Assigned Interventions |
---|---|
All Schizophrenic outpatients who are treated with Seroquel IR and who are additionally intended to start with an integrated care program | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.